U.S. Heart Valves Market Update
The introduction of TAVR began an era of rapid change in the U.S. heart valve market, setting high expectations for other transcatheter valve... In downloads/ July, 2019 Renal Denervation is Making a Comeback – What You Need to Know
In the latest post of this series, we provided an overview on the story of renal denervation and an update on the latest developments in this... In DRG Blog, MedTech/ July, 2019 EuroPCR 2019: 4 Hot Topics to Follow
This year’s EuroPCR conference was abuzz with lots of new innovations and market dynamics impacting the cardiovascular space. Our experts... In DRG Blog, MedTech/ June, 2019 Snapshot of Chronic Heart Failure Disease Management
Understanding Patient Demographics, Treatment Pathways, and Physician Prescribing Behavior How is Chronic Heart Failure Treated Today? Chronic... In DRG Blog, MedTech/ December, 2018 DRG’s Vascular Team: A Retrospective Look at TCT’s 2018 Key Clinical Trials
TCT 2018 was host to the release of data from numerous high-impact clinical trials in the cardiovascular space. Having had some time to... In DRG Blog, MedTech/ October, 2018 4 Takeaways from EuroPCR 2018
Every year, much of the interventional cardiovascular community looks to EuroPCR to witness the latest advances in the way we approach healthcare,... In DRG Blog, MedTech/ June, 2018 TCT 2017 Conference Coverage
The Transcatheter Cardiovascular Therapeutics (TCT) conference is the world’s largest and most important educational meeting specializing in... In downloads/ November, 2017 Acute Heart Failure treatment: pumping strongly or broken hearted?
Despite multiple efforts from pharmaceutical companies at developing drugs to improve the survival and well-being of patients suffering from acute... In DRG Blog, MedTech, Drug Watch/ July, 2017 Market Outlook for Betrixaban: Assessing Portola’s ‘Flagship’ Product in The Medically Ill Patient Population
Portola pharmaceutical’s betrixaban, an oral, once daily factor Xa inhibitor anticoagulant, has been receiving a lot of attention following the... In DRG Blog, MedTech, Drug Watch/ June, 2017 ACC.17: a roller coaster of results
ACC is done for another year, with a multitude of exciting trials presented, including FOURIER, EBBINGHAUS, SPIRE-1 and -2, ORION-1, and CARAT... In DRG Blog, MedTech, Drug Watch/ March, 2017 PCSK9 Inhibitors and Cardiovascular Outcomes: Clinical Success May Not Guarantee Commercial Success
The result for FOURIER, the cardiovascular (CV) outcomes trial for Amgen’s PCSK9 inhibitor Repatha (evolocumab) will be presented in a matter of... March, 2017 Repatha’s FOURIER results: make or break or the same economic ache for PCSK9 inhibitors?
We are potentially on the brink of another massive leap forward in terms of cardiovascular (CV) disease prevention. The first of the late-breaking... In DRG Blog, MedTech, Drug Watch/ March, 2017 The Dyslipidemia Market 2016: Year in Review
Have you ever had that holiday experience, when you thought you were going to receive an amazing gift, but when the big day arrived you got socks?... In DRG Blog, MedTech, Drug Watch/ December, 2016 Is there something fishy about omega-3 fatty acid compounds?
Omega-3 fatty acids are a curious medicinal beast – more than just nutritional supplements, but not fully accepted as a pharmaceutical therapy... In DRG Blog, MedTech, Drug Watch/ October, 2016 Would You Like to Buy a Laser Balloon?
It’s the law of the medtech jungle: big companies buy small companies. Big companies need new technology to out compete other big companies... In DRG Blog, MedTech, Drug Watch/ March, 2016 I Smell Growth: Can the Nose Learn from Heart Attacks?
Cross talk between medtech therapy teams here at DRG is always a pleasant surprise. Xi Chen on the Endoscopy team recently told me that there are... In DRG Blog, MedTech, Drug Watch/ September, 2015